Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug709 | CLBS119 Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001982 | Bronchial Diseases NIH | 0.71 |
| D006969 | Hypersensitivity, Immediate NIH | 0.71 |
| D012130 | Respiratory Hypersensitivity NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.38 |
| D006967 | Hypersensitivity, NIH | 0.32 |
| D007154 | Immune System Diseases NIH | 0.29 |
| D008171 | Lung Diseases, NIH | 0.29 |
| D001249 | Asthma NIH | 0.20 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.18 |
| D012140 | Respiratory Tract Diseases NIH | 0.14 |
| D007249 | Inflammation NIH | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Pulmonary obstruction HPO | 0.38 |
| HP:0012393 | Allergy HPO | 0.32 |
| HP:0002088 | Abnormal lung morphology HPO | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002099 | Asthma HPO | 0.20 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.18 |
Navigate: Correlations HPO
There are 2 clinical trials
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Description: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.
Measure: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies. Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Description: The exacerbation rate is based on exacerbations reported by the investigator over 52 weeks.
Measure: Moderate or severe COPD exacerbation rate ratio (tezepelumab vs placebo) Time: Over 52 WeeksDescription: Time to first occurrence of moderate/severe exacerbation post randomization. Outcome measures: Hazard ratio
Measure: Time to first moderate or severe COPD exacerbation Time: By Week 52Description: Proportion of subjects with at least one moderate/severe exacerbation reported by the Investigator over 52 weeks Outcome measure: Odds Ratio
Measure: Proportion with at least one moderate/severe COPD exacerbation Time: Over 52 WeeksDescription: The severe exacerbation rate is based on severe exacerbations reported by the Investigator over 52 weeks.
Measure: Severe COPD exacerbation rate ratio (tezepelumab vs. placebo) Time: Over 52 WeeksDescription: Difference in change from baseline in pre-BD forced expiratory volume in 1 second (FEV1) in tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.
Measure: Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1) Time: Baseline, Week 52Description: Proportion of subjects achieving a decrease of 4 units or more in the St. George's Respiratory Questionnaire (SGRQ) total score at Week 52, i.e. minimum clinically important difference (MCID). Outcome measure: odds ratio
Measure: Change in respiratory health status/health-related quality of life Time: Baseline, Week 52Description: Difference (tezepelumab vs. placebo) in SGRQ from baseline at Week 52. SGRQ is a 50-item patient reported outcome questionnaire. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0% indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment. Decrease of 4 units is associated with a minimum clinically important difference (MCID).
Measure: Change from baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score Time: Baseline, Week 52Description: Difference (tezepelumab vs. placebo) in COPD assessment tool (CAT) from baseline at Week 52. CAT is an 8-item patient reported outcome questionnaire developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. The score ranges from 0 to 40, with higher scores indicating greater COPD impact on health status.
Measure: Change from baseline in the COPD Assessment Test (CAT) Total Score Time: Baseline, Week 52Description: Serum trough concentration of tezepelumab
Measure: Evaluate pharmacokinetics of tezepelumab Time: Weeks 0, 4, 12, 24, 36, 52, 64Description: Incidence of anti-drug antibodies (ADA)
Measure: Evaluate immunogenicity of tezepelumab Time: Over 52 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports